" class="no-js "lang="en-US"> Imperial College London - Medtech Alert
Sunday, June 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Imperial College London | Pharmtech Focus

Imperial College London

About Imperial College London

Imperial College London

Consistently rated in the top 10 universities in the world, Imperial College London is the only university in the UK to focus exclusively on science, medicine, engineering and business.

At Imperial we bring together people, disciplines, industries and sectors to further our understanding of the natural world, solve major engineering problems, lead the data revolution and improve health and well-being.

Related Story

Diseases

 Novartis Receives GB Licence for Scemblix®▼ (Asciminib)

Novartis Receives GB Licence for Scemblix®▼ (Asciminib), the First STAMP Inhibitor for Patients With Chronic Myeloid Leukaemia

June 17 2022

Novartis UK has announced that Scemblix® (asciminib) has been granted Marketing Authorisation in Great Britain by […]

Diseases

 SomaLogic to Provide 210 Million Protein Measurements to EPIC Researchers to Better Understand and Predict Cancer Development | Pharmtech Focus

SomaLogic to Provide 210 Million Protein Measurements to EPIC Researchers to Better Understand and Predict Cancer Development

March 22 2022

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will […]

Industry News

 VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform | Pharmtech Focus

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

September 23 2021

VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) […]

COVID-19

 Almost 100% of People Have Antibodies After Second Vaccine | Pharmtech Focus

Almost 100% of People Have Antibodies After Second Vaccine

July 16 2021

Imperial College London and Ipsos MORI have today published their latest antibody surveillance report showing, […]